Quantcast

Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?

Research paper by Anuj A Khandelwal, Vincent M VM Crowley, Brian S J BS Blagg

Indexed on: 27 May '15Published on: 27 May '15Published in: Medicinal Research Reviews



Abstract

The 90 kDa heat shock proteins (Hsp90) are responsible for the conformational maturation of nascent polypeptides and the rematuration of denatured proteins. Proteins dependent upon Hsp90 are associated with all six hallmarks of cancer. Upon Hsp90 inhibition, protein substrates are degraded via the ubiquitin-proteasome pathway. Consequentially, inhibition of Hsp90 offers a therapeutic opportunity for the treatment of cancer. Natural product inhibitors of Hsp90 have been identified in vitro, which have served as leads for the development of more efficacious inhibitors and analogs that have entered clinical trials. This review highlights the development of natural product analogs, as well as the development of clinically important inhibitors that arose from natural products.